Mode
Text Size
Log in / Sign up
Phase 4 N=106 Other

A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Well-differentiated Pancreatic Neuroendocrine Tumor

Enrolled (actual)
106
Serious AEs
27.4%
Results posted
May 2017
Primary outcome: Primary: Progression-Free Survival (PFS): Investigator Assessment — 13.2; 13.0 months

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
sunitinib (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Pfizer
Primary completion
Mar 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Progression-Free Survival (PFS): Investigator Assessment
13.2; 13.0
SECONDARY
Progression-Free Survival (PFS): Independent Radiological Review (IRR) Assessment
11.1; 9.5
SECONDARY
Time to Tumor Progression (TTP): Investigator Assessment
14.8; 14.5
SECONDARY
Overall Survival (OS)
NA; 37.9
SECONDARY
Percentage of Participants With Objective Response (OR): Investigator Assessment
21.3; 28.9
SECONDARY
Duration of Response (DOR): Investigator Assessment
19.1; 14.7
SECONDARY
Time to Tumor Response (TTR): Investigator Assessment
3.8; 3.8
SECONDARY
Percentage of Participants With Objective Response (OR): Independent Radiological Review (IRR) Assessment
52.5; 55.6
SECONDARY
Duration of Response (DOR): Independent Radiological Review (IRR) Assessment
NA; 19.2
SECONDARY
Time to Tumor Response (TTR): Independent Radiological Review (IRR) Assessment
1.0; 1.0
SECONDARY
Percentage of Participants With Chromogranin A (CgA) Response
16.4; 11.1
SECONDARY
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)
71.31; 66.09; 69.94; 65.45; 70.30; 60.83
SECONDARY
Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21)
9.47; 15.66; 9.94; 14.91; 14.75; 11.67
SECONDARY
Plasma Concentration of Soluble Protein Biomarker (sKIT)
58218.8; 62267.7; 51614.2; 48946.4; 37705.1; 40334.8
SECONDARY
Minimum Observed Plasma Concentration (Ctrough) of Sunitinib and Its Metabolite SU012662
52.78; 41.93; 42.68; 38.38; 41.79; 38.49
SECONDARY
Dose-Corrected Trough Plasma Concentration of Sunitinib and Its Metabolite SU012662
52.66; 43.38; 42.89; 39.52; 44.99; 38.56
SECONDARY
Area Under the Curve (AUC24) of Sunitinib and Its Metabolite SU012662
SECONDARY
Oral Clearance (CL/F) of Sunitinib and Its Metabolite SU012662
SECONDARY
Half Maximal Effective Concentration (EC50) of Sunitinib
SECONDARY
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
59; 45; 17; 12
SECONDARY
Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)
57; 44; 9; 3
SECONDARY
Number of Participants With Adverse Events (AEs) According to Severity
4; 5; 9; 9; 38; 23
SECONDARY
Number of Participants With Clinically Significant Laboratory Abnormalities
30; 22
SECONDARY
Number of Participants With Change From Baseline in Vital Signs Abnormalities
30; 22
SECONDARY
Number of Participants With Increase From Baseline in Corrected QT Interval (QTc)
0; 0
SECONDARY
Number of Participants With Change From Baseline in Physical Examinations Findings
23; 19
SECONDARY
Number of Participants With Change From Baseline in Body Weight
27; 9; 18; 15
SECONDARY
Number of Participants With Eastern Co-operative Oncology Group Performance Status (ECOG-PS)
37; 25; 15; 14; 9; 6

Summary

The purpose of this study is to confirm the safety and efficacy of sunitinib in subjects with unresectable pancreatic neuroendocrine tumors.

Eligibility Criteria

Inclusion Criteria

  • Histologically or cytologically proven diagnosis of well-differentiated pancreatic neuroendocrine tumor (according to World Health Organization [WHO 2000] classification).
  • Disease progression within 12 months prior to study enrollment.
  • Disease that is not amenable to surgery, radiation, or combined modality therapy with curative intent.

Exclusion Criteria

  • Patients with poorly differentiated pancreatic neuroendocrine tumors (according to WHO 2000 classification).
  • Prior treatment with any tyrosine kinase inhibitors, anti vascular endothelial growth factor (VEGF) angiogenesis inhibitors, non VEGF targeted angiogenesis inhibitors, or mammalian target of rapamycin (mTOR) inhibitors.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01525550). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search